Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy

Abstract Several chronic autoimmune diseases are characterized by elevated autoantibody Fab glycosylation. Whether Fab glycans link to disease state or development remains unclear, yet may serve as a marker thereof. Many autoimmune diseases are treated with B cell depletion therapies that particular...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anika M. Valk, Jana Koers, Ninotska I. L. Derksen, Laura Hogenboom, Zoé van Kempen, Joep Killestein, Abraham Rutgers, Peter Heeringa, Barbara Horváth, Taco W. Kuijpers, S. Marieke van Ham, Anja ten Brinke, Diane van der Woude, René E. M. Toes, Nicolaas A. Bos, Theo Rispens, The T2B consortium
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-04-01
Series:	Scientific Reports
Subjects:	High Fab glycosylation of autoantibodies maintained during B cell depletion therapy Changes in Fab glycosylation of total IgG compartment upon B cell depletion therapy in autoantibody-mediated chronic autoimmune diseases Fab glycosylation autoantibodies B cell depletion therapy Chronic autoimmunity
Online Access:	https://doi.org/10.1038/s41598-025-99226-y
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy

Similar Items